Cubist Systematic Strategies’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $3.84M | Buy |
531,161
+265,174
| +100% | +$1.57M | 0.02% | 1128 |
|
|
2025
Q2 | $1.41M | Buy |
265,987
+148,649
| +127% | +$878K | 0.01% | 1751 |
|
|
2025
Q1 | $1.04M | Sell |
117,338
-154,608
| -57% | -$1.86M | 0.01% | 1792 |
|
|
2024
Q4 | $3.73M | Sell |
271,946
-986
| -0.4% | -$18.2K | 0.02% | 1000 |
|
|
2024
Q3 | $7.48M | Buy |
+272,932
| New | +$7.39M | 0.05% | 610 |
|
|
2023
Q4 | – | Sell |
-130,509
| Closed | -$2.09M | – | 3912 |
|
|
2023
Q3 | $2.09M | Buy |
130,509
+76,740
| +143% | +$1.46M | 0.02% | 1335 |
|
|
2023
Q2 | $1.25M | Sell |
53,769
-21,159
| -28% | -$462K | 0.01% | 1820 |
|
|
2023
Q1 | $1.74M | Buy |
74,928
+30,856
| +70% | +$627K | 0.01% | 1763 |
|
|
2022
Q4 | $639K | Buy |
44,072
+2,878
| +7% | +$53.6K | ﹤0.01% | 2843 |
|
|
2022
Q3 | $786K | Buy |
41,194
+11,907
| +41% | +$273K | ﹤0.01% | 2822 |
|
|
2022
Q2 | $532K | Buy |
29,287
+11,762
| +67% | +$244K | ﹤0.01% | 3011 |
|
|
2022
Q1 | $442K | Buy |
+17,525
| New | +$448K | ﹤0.01% | 2615 |
|
|
2021
Q4 | – | Sell |
-14,328
| Closed | -$463K | – | 3564 |
|
|
2021
Q3 | $463K | Buy |
14,328
+8,427
| +143% | +$280K | 0.01% | 2085 |
|
|
2021
Q2 | $180K | Sell |
5,901
-2,785
| -32% | -$80.5K | ﹤0.01% | 2600 |
|
|
2021
Q1 | $264K | Sell |
8,686
-35,125
| -80% | -$997K | ﹤0.01% | 2327 |
|
|
2020
Q4 | $866K | Sell |
43,811
-66,016
| -60% | -$1.07M | 0.01% | 1471 |
|
|
2020
Q3 | $1.43M | Sell |
109,827
-72,290
| -40% | -$915K | 0.02% | 1115 |
|
|
2020
Q2 | $2.06M | Buy |
182,117
+88,176
| +94% | +$1.25M | 0.04% | 774 |
|
|
2020
Q1 | $1.34M | Buy |
93,941
+82,292
| +706% | +$1.74M | 0.04% | 656 |
|
|
2019
Q4 | $317K | Sell |
11,649
-10,194
| -47% | -$280K | 0.01% | 1816 |
|
|
2019
Q3 | $625K | Sell |
21,843
-13,318
| -38% | -$388K | 0.01% | 1188 |
|
|
2019
Q2 | $977K | Sell |
35,161
-25,284
| -42% | -$714K | 0.02% | 1058 |
|
|
2019
Q1 | $2.01M | Buy |
60,445
+30,343
| +101% | +$924K | 0.07% | 440 |
|
|
2018
Q4 | $875K | Buy |
30,102
+28,797
| +2,207% | +$1.04M | 0.04% | 630 |
|
|
2018
Q3 | $60K | Buy |
1,305
+1,005
| +335% | +$44.7K | ﹤0.01% | 1683 |
|
|
2018
Q2 | $11K | Sell |
300
-4,804
| -94% | -$162K | ﹤0.01% | 1720 |
|
|
2018
Q1 | $151K | Sell |
5,104
-1,125
| -18% | -$38.1K | 0.01% | 1498 |
|
|
2017
Q4 | $214K | Sell |
6,229
-22,183
| -78% | -$748K | 0.01% | 1489 |
|
|
2017
Q3 | $1.03M | Buy |
+28,412
| New | +$810K | 0.06% | 418 |
|
|
2016
Q3 | – | Sell |
-50,262
| Closed | -$1.54M | – | 1802 |
|
|
2016
Q2 | $1.54M | Buy |
50,262
+12,723
| +34% | +$442K | 0.09% | 283 |
|
|
2016
Q1 | $1.41M | Buy |
+37,539
| New | +$1.41M | 0.08% | 333 |
|
|
2015
Q4 | – | Sell |
-6,700
| Closed | -$251K | – | 1877 |
|
|
2015
Q3 | $251K | Buy |
+6,700
| New | +$238K | 0.01% | 1347 |
|
|
2015
Q2 | – | Sell |
-689
| Closed | -$24K | – | 1962 |
|
|
2015
Q1 | $24K | Buy |
+689
| New | +$24.7K | ﹤0.01% | 1815 |
|
Other funds holding MYGN
GCM
Cubist Systematic Strategies's MYGN Position: Q3 2025 in Review
Cubist Systematic Strategies increased its Myriad Genetics (MYGN) stake by 100% in Q3 2025, buying an estimated $1.57M and bringing the position to 531,161 shares worth $3.84M. The position accounts for 0.02% of the portfolio, ranked #1128.
Cubist Systematic Strategies first reported a position in MYGN in Q1 2015 and has held it in 33 quarters since. The position peaked at $7.48M in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.
- Cubist Systematic Strategies held 531,161 shares of Myriad Genetics worth $3.84M as of Q3 2025.
- Cubist Systematic Strategies bought 265,174 Myriad Genetics shares in Q3 2025, an estimated $1.57M.
- Myriad Genetics made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1128 holding.
- Cubist Systematic Strategies first reported a position in Myriad Genetics in Q1 2015 and has held it in 33 quarters since.
- Cubist Systematic Strategies's Myriad Genetics position peaked at $7.48M in Q3 2024.
- 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.